Last reviewed · How we verify

EVIVE Biotechnology — Portfolio Competitive Intelligence Brief

EVIVE Biotechnology pipeline: 2 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 1 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
RYZNEUTA EFBEMALENOGRASTIM ALFA-VUXW marketed Leukocyte Growth Factor [EPC] specific cell surface receptors Other
GRAN® GRAN® marketed 5-hydroxytryptamine receptor 3B, Multidrug and toxin extrusion protein 1, Solute carrier family 22 member 2 Other
F-627 F-627 phase 3 G-CSF receptor agonist G-CSF receptor (CSF3R) Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. · 1 shared drug class
  2. Amgen · 1 shared drug class
  3. Berlex Labs · 1 shared drug class
  4. FRESENIUS KABI USA · 1 shared drug class
  5. KASHIV BIOSCIENCES LLC · 1 shared drug class
  6. LUPIN LTD · 1 shared drug class
  7. MYLAN GMBH · 1 shared drug class
  8. SANDOZ INC · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for EVIVE Biotechnology:

Cite this brief

Drug Landscape (2026). EVIVE Biotechnology — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/evive-biotechnology. Accessed 2026-05-15.

Related